ESMO News

Machine Learning Could Help Identify People at Higher Risk of Common Cancers Using Routine Health Data

noreply@esmo.org — Mon, 26 Oct 2026 07:30:00 +0000

Machine learning models using routinely collected health information, such as blood tests, medical history and lifestyle factors, could help identify people at higher risk of several common cancers, according to an international study reported at the ESMO Congress 2026

Omega-3 EPA Linked to Longer Survival After Surgery for Colorectal Cancer Liver Metastases

noreply@esmo.org — Sun, 25 Oct 2026 09:15:00 +0000

Patients assigned to receive high-dose eicosapentaenoic acid (EPA), an omega-3 fatty acid, before and after surgery for colorectal cancer liver metastases had longer overall survival than those assigned to receive placebo, according to results of the phase 3 EMT2 trial presented at the ESMO Congress 2026.

Personalised Cancer Vaccine Plus Immunotherapy Reduces Melanoma Recurrence After Surgery

noreply@esmo.org — Sat, 24 Oct 2026 16:30:00 +0000

Adding a personalised mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase 3 INTerpath-001 trial presented at the ESMO Congress 2026

Adding Abiraterone to ADT and Docetaxel Improves Survival in Metastatic Prostate Cancer

noreply@esmo.org — Sat, 24 Oct 2026 08:15:00 +0000

Adding abiraterone to standard treatment provides a lasting survival benefit for men whose prostate cancer has already spread at diagnosis, reinforcing the value of early treatment intensification. The findings come from almost eight years of follow-up in the academically led phase 3 PEACE-1 trial presented at the ESMO Congress 2026.

Thymus Radiation is Linked to Worse Outcomes in Patients with Non-Small Cell Lung Cancer

noreply@esmo.org — Wed, 26 Aug 2026 06:00:00 +0000

Until recently, the thymus was thought to be of little use beyond puberty, but new research has shown that radiation to the organ is associated with worse outcomes in patients being treated for non-small cell lung cancer (NSCLC).

Blood Test May Help Identify Which Colorectal Cancer Patients with Liver Metastases Are Most Likely to Benefit from Chemotherapy After Surgery

noreply@esmo.org — Fri, 03 Jul 2026 14:30:00 +0000

A blood test may help identify which patients with colorectal cancer that has spread to the liver are most likely to benefit from chemotherapy after surgery, according to research presented today at the ESMO Gastrointestinal Cancers Congress 2026

New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer

noreply@esmo.org — Thu, 02 Jul 2026 14:54:00 +0000

An investigational targeted therapy designed to block one of the most common genetic drivers of pancreatic cancer has shown promising early results when combined with standard first-line chemotherapy, according to research presented today at the ESMO Gastrointestinal Cancers Congress 2026

ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific

noreply@esmo.org — Fri, 12 Jun 2026 08:06:00 +0000

The second edition of the ESMO TAT Asia Congress 2026, taking place from 12 to 14 June in Hong Kong SAR, China, reflects ESMO’s ongoing commitment to working alongside the Asia-Pacific oncology community and fostering global collaboration in developing new anti-cancer therapies.

Weight Loss Treatments Linked to Lower Risk of Obesity-Related Cancers in People Without Diabetes

noreply@esmo.org — Mon, 08 Jun 2026 12:00:00 +0000

A study of more than 229,000 obese adults without diabetes in the United States has shown that weight loss drugs are associated with a decreased risk of obesity-related cancers.

National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors

noreply@esmo.org — Thu, 07 May 2026 07:28:00 +0000

Hundreds of thousands of people diagnosed with cancer are still alive today but were never genetically tested, either because testing was not available or was not routinely offered at the time of their diagnosis

Population-based lung cancer screening can reduce mortality in people who have never smoked, study shows in China

noreply@esmo.org — Fri, 27 Mar 2026 13:45:00 +0000

New evidence from a Chinese cohort presented today at the European Lung Cancer Congress (ELCC) 2026 shows that onetime ‑lowdose computed tomography (LDCT) screening can significantly reduce lung cancer mortality in a non–risk‑ based population, including individuals with no smoking history.

New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers

noreply@esmo.org — Thu, 12 Mar 2026 08:00:00 +0000

ESMO and EURACAN call for policy action to standardise care pathways for rare cancers after analysis links guideline adherence to patient survival

Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off

noreply@esmo.org — Mon, 19 Jan 2026 00:05:00 +0000

After increasing for more than 25 years, lung cancer death rates are finally levelling off among women in European Union (EU) countries apart from Spain, according to predictions of mortality rates from the disease for 2026

AI Model Identifies How Every Country Can Improve Its Cancer Outcomes

noreply@esmo.org — Wed, 14 Jan 2026 00:00:00 +0000

For the first time, researchers have used machine learning – a type of artificial intelligence (AI) – to identify the most important drivers of cancer survival in nearly all the countries in the world

Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance

noreply@esmo.org — Thu, 04 Dec 2025 13:25:00 +0000

The ESMO Immuno-Oncology Congress 2025 will take place from 10–12 December in London, UK, bringing together specialists in cancer immunotherapy to present and discuss research in this promising field, spanning all areas from basic and translational science to the latest clinical developments

Shaping Cancer Care in Asia: ESMO Brings Research and Patient Voices to the Forefront at the Congress in Singapore

noreply@esmo.org — Fri, 28 Nov 2025 08:52:00 +0000

Taking place from 5–7 December, the ESMO Asia Congress is the multidisciplinary event that brings together oncology professionals from across the Asia-Pacific region and beyond

New Generation of Antibody-Drug Conjugates (ADCs) Shows Unprecedented Promise in Early-Stage Disease

noreply@esmo.org — Sat, 18 Oct 2025 11:14:00 +0000

In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs)—can dramatically improve outcomes for patients with early-stage HER2-positive breast cancer

Study Shows Thymic Health is Linked to Cancer Patients’ Response to Immunotherapy

noreply@esmo.org — Thu, 16 Oct 2025 14:04:00 +0000

The health of the thymus – a key part of the body’s immune system - is associated with cancer patients’ outcomes to immune checkpoint inhibitor treatment, according to a ground-breaking international study reported at ESMO 2025.

ESMO 2025: A Glimpse Into the Congress Programme, Berlin, Germany, 17-21 October

noreply@esmo.org — Mon, 13 Oct 2025 12:14:00 +0000

The ESMO Congress 2025 will take place from 17-21 October in Berlin, Germany, where internationally renowned oncology experts will present cutting-edge data and engage in thought-provoking discussions covering the current advances and future directions of oncology research and care

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:21:00 +0000

The Molecular Analysis for Precision Oncology Congress 2025 (MAP) will bring together leading experts to explore the latest advances in cancer research, with a focus on deepening the understanding of disease mechanism and enhancing strategies for prevention and interception